Cargando…

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when recurrence score (RS) was ≥31. HER2 is a component of the RS alg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geyer, Charles E., Tang, Gong, Mamounas, Eleftherios P., Rastogi, Priya, Paik, Soonmyung, Shak, Steven, Baehner, Frederick L., Crager, Michael, Wickerham, D. Lawrence, Costantino, Joseph P., Wolmark, Norman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235896/ https://www.ncbi.nlm.nih.gov/pubmed/30456299 http://dx.doi.org/10.1038/s41523-018-0090-6

Ejemplares similares

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
por: Sparano, Joseph A., et al.
Publicado: (2021)

Clinical relevance of the 21-gene Recurrence Score(®) assay in treatment decisions for patients with node-positive breast cancer in the genomic era
por: Mamounas, Eleftherios P., et al.
Publicado: (2018)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
por: Denkert, Carsten, et al.
Publicado: (2023)

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
por: Perez, Edith A., et al.
Publicado: (2015)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
por: Gunia, Sommer R., et al.
Publicado: (2012)

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death
por: Baehner, FL, et al.
Publicado: (2009)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier
por: Seo, Mi-kyoung, et al.
Publicado: (2020)

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
por: Conte, PierFranco, et al.
Publicado: (2020)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group
por: Ganz, Patricia A., et al.
Publicado: (2009)

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
por: Petkov, Valentina I, et al.
Publicado: (2016)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
por: Petkov, Valentina I, et al.
Publicado: (2018)

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2022)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
por: Lin, Hao-Kuen, et al.
Publicado: (2023)

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
por: Solin, Lawrence J., et al.
Publicado: (2013)

Promoting an Inclusive Approach to Benefit Sharing: Expanding the Scope of the CBD?
por: Chaturvedi, Sachin, et al.
Publicado: (2013)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score
por: Paik, Soonmyung, et al.
Publicado: (2021)

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry
por: Baehner, FL, et al.
Publicado: (2009)

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
por: Paterson, Alexander H G, et al.
Publicado: (2021)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
por: Kim, Hyun Seok, et al.
Publicado: (2015)

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
por: Zhang, Wen-Wen, et al.
Publicado: (2019)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
por: Nitz, Ulrike, et al.
Publicado: (2020)

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
por: Alvarado, Michael D., et al.
Publicado: (2015)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
por: Lim, Sun Min, et al.
Publicado: (2016)

Safety Profile of Amnion-Derived Cellular Cytokine Solution (ACCS) Following Topical Skin Application in Patients Receiving Breast Radiotherapy
por: Trombetta, Mark, et al.
Publicado: (2015)

Molecular characterization of breast cancer needle core biopsy specimens by the 21‐gene Breast Recurrence Score test
por: Jakubowski, Debbie M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ipnjbgm3iuect7tv5tqjfvtlih